Our ambition is not only to sustain our Impact and ESG approach, but to ensure that it more directly reflects the real-world outcomes our portfolio can ultimately deliver. 

While most of our portfolio companies are still in early development stages and have not yet brought products to market, they are advancing therapies that have meaningful potential to address high unmet medical needs. This future-oriented impact will continue to guide our priorities and decision-making.

Our portfolio holds extraordinary promise to transform current standards of care. We are committed to placing greater emphasis on identifying, articulating, and measuring potential impact in the near future, focusing on the patients our innovations aim to reach and the outcomes they seek to improve.

Beyond human health, we also recognize our opportunity to positively contribute to planetary health. Through our BioEconomy fund, we invest in companies developing innovative solutions that can reduce environmental impact, enhance resource efficiency, and support the transition to more sustainable future. We will continue to highlight and advance this dimension of our impact, ensuring it is an integral part of how we assess and support our portfolio. At the same time, we will intensify our engagement with portfolio companies, working closely with management teams to embed sustainability considerations early.

Maximizing impact requires collective action. We will aim to strengthen our collaboration with peers and investors, contributing to the development of shared frameworks and higher standards for sustainability in healthcare and beyond. By aligning around common goals, we are confident that we can extend our reach and help drive meaningful change.